Pharmaceutical and Medicine Manufacturing (United States) — NAICS 3254

NAICS 2022 industry group 3254. NAICS = North American Industry Classification System, the U.S. government's standard scheme for grouping businesses. This is a four-digit "industry group" that sits inside the broader Chemical Manufacturing subsector (325) and, one level down, contains exactly one industry: 32541.

Short page, by design. This industry group has a single child, so 3254 and 32541 describe the same set of factories, the same output, and the same companies. This page gives the level's own federal figures and the one-paragraph version of each topic, then points you to the full leaf primer. For the detailed treatment — the four sub-industries, the investable names, the economics of each, and the risk map — read the 32541 primer.

---

1. Overview

This is the whole of U.S. medicine-making under one code: the businesses that make the active ingredients, the finished pills and shots, the vaccines and cell therapies, and the diagnostic reagents that the health-care system runs on. If a product is manufactured, given to (or tested on) a patient, and regulated by the Food and Drug Administration (FDA) as a drug, biologic, or diagnostic, its factory is inside NAICS 3254.

Why an investor should care: this is one of the largest, most defensive, highest-margin, and most heavily regulated manufacturing industries in the economy. Demand — an aging, chronically ill population that keeps taking medicine through booms and recessions — is durable and largely non-cyclical; a 2025 CDC study found 76% of U.S. adults reported at least one chronic condition and 51% reported two or more [1]. But the industry is really four different businesses stapled together by a shared regulator: one runs on patent monopolies, one on biological exclusivity, one on a razor-and-blade annuity, and one on commodity chemistry. Those four live inside the single child, 32541 — which is why this level and that one are the same thing.

---

2. What's inside — and why this level equals its one child

The NAICS hierarchy nests: subsector 325 (all chemical manufacturing) contains the industry group 3254 (pharmaceuticals and medicine), which contains one industry, 32541, which then splits into four national industries:

• 325411 — Medicinal and Botanical Manufacturing — bulk active pharmaceutical ingredients (APIs), the raw drug substance; ~6% of the level's receipts but a quarter of its plants.
• 325412 — Pharmaceutical Preparation Manufacturing — finished dose forms (tablets, capsules, injectables); ~64% of the level.
• 325413 — In-Vitro Diagnostic Substance Manufacturing — the reagents and test kits used to test samples taken outside the body; ~10%.
• 325414 — Biological Product (except Diagnostic) Manufacturing — biologics: vaccines, plasma therapies, monoclonal antibodies, and gene and cell therapies; ~20%, and the fastest-growing of the four.

The one-line reading: 325412 is the giant most people picture when they hear "the pharma industry"; 325414 is the smaller but faster-growing future of medicine — FDA noted in March 2026 that biologics are only 5% of U.S. prescriptions but 51% of drug spending [4]; 325413 is a sticky, high-quality annuity; and 325411 is a small, strategically contested, mostly-imported upstream link that policy is now trying to rebuild.

Why 3254 = 32541. An industry group can hold several industries; this one holds only one. There is no second industry at this level for 3254's totals to absorb, so every figure for 3254 is, by construction, the figure for 32541 — and both are simply the sum of the four national industries above. One counting wrinkle is worth knowing at this level: because the codes predate the biologics boom and big companies straddle them (a Roche or an Abbott spans three children at once), the four children list 2,292 firms between them while the industry as a whole counts 2,222 [2] — a firm operating in more than one child is counted once here. This page adds no new economics; it exists to give the four-digit level its own ground-truth numbers and route you to the child for detail.

---

3. How big it is (federal ground truth)

Our ingested federal statistics for NAICS 3254 (identical to 32541, per Section 2):

Inside that total, the weight sits heavily in finished drugs — $149.9 billion (64.0% of receipts) and 53% of the jobs — followed by biologics ($47.3 billion, 20.2%), diagnostic reagents ($23.1 billion, 9.9%), and bulk APIs ($13.9 billion, 5.9%) [2][3]. Two patterns are visible only at this level. First, plants and revenue do not line up: API making holds a quarter of all establishments on under 6% of receipts, spread across many small, low-wage sites (~$77,000 average pay, against ~$125,000 in biologics and ~$115,000 in diagnostics). Second, the wage gradient tracks the science, and even the low end is a good job — the group average of ~$114,000 sits far above the manufacturing norm, reflecting regulated, skilled work throughout. (The full per-child breakdown is in Section 3 of the 32541 primer.)

Undercount caveat (large, and it runs two ways). The $234.2 billion is U.S. domestic factory-gate output — the value of what plants on U.S. soil ship, before wholesale, pharmacy, and middleman markups. It is neither what Americans spend on medicine nor the global revenue of the companies involved. It sits below true consumption because so much of what the U.S. uses is imported: FDA reports that roughly 53% of branded and 69% of generic finished drugs distributed here are made abroad, and only 11% of API manufacturers are U.S.-based [6]. The gaps are stark child by child — U.S. prescription-drug spending alone was about $805.9 billion in 2024 [5], more than triple this industry's entire domestic output, and private estimates put the U.S. API market near $87 billion [7] against $13.9 billion of domestic API shipments, with the U.S. biologics market well north of $200 billion [9]. The figure also excludes the industry's research staff, headquarters, and sales forces, which file under other codes — the 321,068 factory workers here understate a biopharmaceutical industry that directly employs over 1 million Americans [10]. Finally, a dispersed, easily-misclassified small-owner tail (herbal, cannabinoid, vitamin, and supplement-ingredient makers, often filed into food or chemical codes) means the count is a floor, not a ceiling, wherever small and individual ownership dominates. Read $234 billion as an accurate measure of the domestic manufacturing footprint, sitting inside a much larger consumption economy served heavily from abroad.

---

4. The investable universe — where value concentrates

All the public liquidity, and nearly all the private value, lives inside the four children — reached identically whether you label the level 3254 or 32541. In brief:

• Finished drugs (325412) hold almost all the public liquidity — the household names, directly or as American Depositary Receipts (ADRs, U.S.-traded certificates for foreign shares), plus the generics and contract makers below them.
• Biologics (325414) are owned in focused pieces — a few pure-plays, plasma majors (mostly foreign-listed), the biologic franchises buried inside diversified pharma, and, for biodefense and vaccines, the U.S. government as customer.
• Diagnostic reagents (325413) have no pure-play stock; they are a high-margin segment inside diversified device and life-science leaders, with a handful of harder-tilted mid-caps.
• Bulk APIs (325411) have no U.S. pure-play at all; exposure comes from foreign-listed API/contract specialists, diversified names, ingredient and nutrition firms, and — most purely — private owners.

The purest assets, in every child, are frequently private: contract developers/manufacturers, plasma fractionators, and the botanical/vitamin tier. The emblem is Catalent — a leading contract developer spanning API, fill-finish, and biologics work — taken private by Novo Holdings for about $16.5 billion in December 2024 [11]. (Named tickers, private owners, and the routes to each child are laid out in Section 4 of the 32541 primer.)

---

5. How the money works

The four children share defensive demand, high fixed costs, and a regulatory moat — but the source of the moat differs, and so do the economics: a patent monopoly (325412, 70–90% gross margins on a near-costless pill, with generics as the thin-margin mirror image); 12-year biological exclusivity plus keeping billion-dollar bioreactors full (325414, where plasma is a vertically integrated supply-chain business of its own); a razor-and-blade annuity where you place an analyzer and sell its proprietary reagents for years on 5–7-year lab contracts (325413); and specialty-process chemistry where plant utilization is the main profit lever and a filed ingredient dossier is the moat (325411). How owners get paid differs too — mature firms pay dividends and buy back stock, clinical-stage biotech burns cash, and royalty investors buy a slice of future drug sales. See Section 5 of the 32541 primer for each model in full.

---

6. What drives demand

Demand is mostly shared, which is what makes the industry defensive: aging and chronic disease (the structural, non-cyclical base — Census projects the 65-and-over share of Americans will surpass the under-18 share in 2029 [12]); the obesity/GLP-1 wave (glucagon-like peptide-1 receptor agonists — the diabetes/weight-loss class — roughly 29% of all 2024 U.S. drug-spending growth [5], pulling demand through finished drugs, APIs, and fill-finish at once); the shift toward biologics, where the sources genuinely disagree on how far it has already gone — commonly put at ~37–38% of U.S. prescription spending [9], while FDA said in March 2026 that biologics account for 51% of drug spending on just 5% of prescriptions [4]; take the direction, not the decimal; molecular and point-of-care testing broadening the reagent base; and, newly, supply-security and reshoring policy as a demand driver for domestic capacity in its own right.

---

7. Regulation

Medicine manufacturing is among the most heavily regulated activity in the economy, and the FDA is the common overlord across all four children — current Good Manufacturing Practice (cGMP), routine plant inspections, warning letters, import alerts, and recalls. Above that shared floor, approval pathways differ by child (New/Abbreviated Drug Applications for small-molecule drugs; a Biologics License Application for biologics, with 82 biosimilars approved as of March 2026 [4]; device clearances for diagnostics; confidential Drug Master Files for APIs). Two policies dominate the current picture. The Inflation Reduction Act's Medicare price negotiation is a structural headwind to branded pricing — the first 10 negotiated prices take effect January 2026, at least 38% below 2023 list prices [13], and the law is not neutral across the children: biologics get about 13 years of market pricing before negotiation bites versus 9 years for small-molecule pills, a gap that steers investment toward large molecules [14]. And Section 232 trade tariffs (an April 2026 action on certain patented pharmaceuticals and ingredients) are tiered — a 100% default rate, cut to 20% for firms with approved onshoring plans, 15% for EU, Japanese, South Korean, and Swiss product, and 0% for firms signing pricing-and-onshoring agreements, phasing in from July 31, 2026 — aimed at an API base of which only about 15% of patented volume is made domestically [15]. One child carries its own live swing: FDA's rule to regulate laboratory-developed tests as devices was vacated in March 2025 and rescinded that September [16], leaving diagnostic kit makers fully regulated while their lab-based competitors are not. Details are in Section 7 of the 32541 primer.

---

8. Consolidation

The federal concentration data make the industry look strikingly unconcentrated — CR4 of just 28.4% and an HHI of 313.7 [2], far below the 1,500 antitrust threshold. Treat that as partly a statistical illusion of aggregation: pooling four industries whose leaders are largely different companies in different markets mechanically dilutes measured concentration (the level's HHI of 314 is actually lower than its dominant finished-drug child's 557 and its diagnostics child's 752). Within any single drug, disease, or testing category, competition is far more concentrated than the number suggests — and the plasma business is a tight oligopoly, with four firms controlling an estimated 70–80% of U.S. collection and fractionation [17]. The real consolidation is intense: M&A as patent-cliff pipeline insurance (2025 pharma M&A ~$240 billion, up 81% year over year [19], against a 2026–2030 cliff of over $230 billion in revenue across ~190 drugs [18]); contract-manufacturing roll-up (the $16.5 billion Catalent take-private [11], plus roughly $24.9 billion of new CDMO capacity announced in 2025, ~74% of it flowing to the United States [20]); diagnostics reshuffling; and a tariff-driven reshoring capex cycle in which drugmakers have pledged on the order of $500 billion in new U.S. manufacturing, nearly $283 billion of it since the 2025 trade action opened [21]. Full treatment in Section 8 of the 32541 primer.

---

9. Risks

The headline risks are shared across the children: patent and exclusivity cliffs (a top drug's revenue can fall 80–90% within a year of generic or biosimilar entry, and 2026–2030 is an exceptionally heavy wave — ~190 drugs, about 69 of them blockbusters [18]); pricing and policy pressure (IRA negotiation, widening yearly, plus middleman reform [13]); import dependence and tariff whiplash (U.S. pharmaceutical imports jumped from $73 billion in 2014 to $215 billion in 2024 [21], only 11% of API manufacturers are U.S.-based [6], and new tariffs can raise the cost of the very inputs domestic producers still rely on [15]); manufacturing and quality failure (a failed inspection or contamination can halt a line overnight — FDA names manufacturing-quality problems as the most common cause of drug shortages, with limited alternative capacity making recovery slow [21]); and pipeline binary risk (most candidates fail, and value is concentrated in individual products). Child-specific tails — opioid and controlled-substance litigation, plasma-supply and lumpy government demand, post-COVID diagnostics normalization and lab-reimbursement cuts, commodity-generic deflation — are catalogued in Section 9 of the 32541 primer.

---

10. How to invest, and the outlook

Because 3254 equals its one child, the routes to invest are identical to those in the 32541 primer: broad, liquid, defensive exposure via finished-drug majors and sector/biotech ETFs (exchange-traded funds); the fastest-growing slice via biologics pure-plays, plasma majors, and bioprocessing-tools suppliers; a sticky annuity via the diversified diagnostics leaders and harder-tilted mid-caps; the strategic upstream via foreign-listed API/contract specialists and ingredient firms; and the purest assets, which are private in every child — private equity, venture capital, drug royalties, and government-contractor plays.

The reasonable read. Expect durable, largely recession-proof volume growth in medicine overall; branded pricing power narrowing under policy pressure; biologics taking a rising share of both spending and new capacity; diagnostics compounding steadily as an annuity; and a gradual, capital-intensive, incomplete reshoring of the API base that is real but constrained by a persistent cost gap. The industry stays large, defensive, and profitable — but the growth, the risk, and the way to own it differ sharply depending on which of the four children you are actually buying. For that detail, go to the 32541 primer.

---

Sources

1. Centers for Disease Control and Prevention. "Prevalence of Chronic Conditions Among US Adults, 2023" (76% with ≥1 chronic condition; 51% with two or more). Preventing Chronic Disease. 2025. https://www.cdc.gov/pcd/issues/2025/24_0539.htm
2. U.S. Census Bureau. "2022 Economic Census — Concentration Ratios and Receipts, NAICS 32541/3254" (receipts $234.2B; firms 2,222; CR4 28.4% / CR8 40.8% / CR20 57.4% / CR50 71.6%; HHI 313.7; child receipts and HHIs). Ground-truth federal data. https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Census Bureau. "County Business Patterns 2023 — NAICS 32541/3254" (establishments 2,905; employment 321,068; annual payroll ~$36.5B; child employment and pay). Ground-truth federal data. https://www.census.gov/programs-surveys/cbp.html
4. U.S. Food and Drug Administration. "FDA Takes Further Steps to Streamline Biosimilar Development" (82 biosimilars approved; biologics 5% of prescriptions, 51% of drug spending). March 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable
5. PharmExec (MJH Life Sciences) / ASHP. "GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024" ($805.9B; GLP-1 ~29% of growth). 2025. https://www.pharmexec.com/view/glp-1-surge-fuels-10-2-rise-us-prescription-drug-spending-2024
6. U.S. Food and Drug Administration. "FDA Manufacturing PreCheck Pilot Program" (53% branded / 69% generic finished drugs manufactured abroad; 11% of API manufacturers U.S.-based). 2025. https://www.fda.gov/industry/fda-manufacturing-precheck-pilot-program
7. Grand View Research. "U.S. Active Pharmaceutical Ingredients Market Report" (~$87B, 2024). 2024. https://www.grandviewresearch.com/industry-analysis/us-active-pharmaceutical-ingredients-market-report
8. Grand View Research / JAMA. "Biologics Market; biologics ~37–38% of U.S. drug spending; U.S. market >$200B." 2025. https://www.grandviewresearch.com/industry-analysis/biologics-market
9. PhRMA / TEConomy Partners. "The Economic Impact of the U.S. Biopharmaceutical Industry" (>1M direct jobs; ~$96B R&D in 2023). 2024. https://phrma.org/resources/industry-economic-impact
10. BioProcess International. "Novo Holdings to buy CDMO Catalent for $16.5bn." 2024. https://www.bioprocessintl.com/facilities-capacity/novo-holdings-16-5bn-catalent-buy-to-boost-fill-finish-for-novo-nordisk-
11. U.S. Census Bureau. "2023 Population Projections" (65+ share to surpass under-18 share in 2029). 2023. https://www.census.gov/newsroom/press-releases/2023/population-projections.html
12. Centers for Medicare & Medicaid Services. "Medicare Drug Price Negotiation Program: Negotiated Prices for 2026" (first 10 prices, ≥38% below 2023 list). 2025. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
13. Congressional Research Service / KFF. "Medicare Drug Price Negotiation under the IRA" (13 vs 9 years of market pricing for biologics vs small molecules). 2025. https://www.congress.gov/crs-product/R47872
14. The White House / Crowell & Moring / BioPharma Dive. "Section 232 tariffs on patented pharmaceutical products and ingredients" (100% default, tiered carve-outs at 20%/15%/0%; ~15% of patented APIs by volume domestic; phasing in from July 31, 2026). 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/
15. Covington & Burling / Arnold & Porter. "FDA's LDT Rule Struck Down" (May 2024 rule; vacated March 2025; rescinded September 2025). 2025. https://www.cov.com/en/news-and-insights/insights/2025/04/fdas-ldt-rule-struck-down-by-federal-district-court
16. PR Newswire / MarketsandMarkets. "Plasma Fractionation Market — CSL, Grifols, Takeda, Octapharma (~70–80% of U.S. collection and fractionation)." 2024–2025. https://www.marketsandmarkets.com/ResearchInsight/plasma-fractionation-market.asp
17. Drug Discovery News. "Blockbuster drugs face a massive patent cliff in 2026" (>$230B, ~190 drugs, ~69 blockbusters, 2025–2030). 2025. https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019
18. BS Capital Markets. "Patent Cliffs and the New Pharma M&A Cycle" (2025 M&A ~$240B, +81% YoY). 2026. https://www.bscapitalmarkets.com/patent-cliffs-and-the-new-pharma-ma-cycle.html
19. PharmaSource. "The Great Reshoring: How $24.86 Billion Reshaped CDMO Manufacturing in 2025" (~74% to the U.S.). 2025. https://pharmasource.global/content/news/cdmo-news/the-great-reshoring-how-24-86-billion-reshaped-cdmo-manufacturing-in-2025/
20. Coalition for a Prosperous America. "Skyrocketing Pharmaceutical Imports to the U.S." (imports $73B→$215B; ~$283B in reshoring pledges since the trade action). 2025. https://prosperousamerica.org/skyrocketing-pharmaceutical-imports-to-the-u-s-endanger-national-security/
21. U.S. Food and Drug Administration. "Frequently Asked Questions About Drug Shortages" (manufacturing quality as most common cause). 2025. https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages